NASDAQ:BCRX • US09058V1035
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOCRYST PHARMACEUTICALS INC (BCRX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-05 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-04 | Needham | Maintains | Buy -> Buy |
| 2025-11-04 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-15 | TD Cowen | Reiterate | Buy |
| 2025-10-15 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-10-15 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-10-15 | Needham | Maintains | Buy -> Buy |
| 2025-08-04 | Needham | Maintains | Buy -> Buy |
| 2025-07-01 | B of A Securities | Maintains | Buy -> Buy |
| 2025-06-30 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-06-30 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-06-27 | Needham | Reiterate | Buy -> Buy |
| 2025-06-25 | Needham | Reiterate | Buy -> Buy |
| 2025-05-07 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-06 | Needham | Maintains | Buy -> Buy |
| 2025-05-06 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-05-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-29 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-04-11 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
| 2025-03-03 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-25 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 331.412M 22.38% | 450.712M 36.00% | 874.837M 94.10% | 663.77M -24.13% | 747.06M 12.55% | 892.37M 19.45% | 1.097B 22.93% | 1.323B 20.60% | 1.499B 13.30% | 1.645B 9.74% | 1.686B 2.49% | |
| EBITDA YoY % growth | -100.506M 31.61% | -1.297M 98.71% | 342.378M 26,497.69% | 53.55M -84.36% | 80.774M 50.84% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -102.161M 31.16% | -2.543M 97.51% | 340.989M 13,508.93% | 104.4M -69.38% | 163.7M 56.80% | 231.07M 41.15% | 403.05M 74.43% | 570.52M 41.55% | 697.41M 22.24% | 810.35M 16.19% | 887.42M 9.51% | |
| Operating Margin | -30.83% | -0.56% | 38.98% | 15.73% | 21.91% | 25.89% | 36.74% | 43.12% | 46.53% | 49.26% | 52.63% | |
| EPS YoY % growth | -0.99 25.56% | -0.43 56.57% | 0.11 125.58% | 0.30 172.89% | 0.50 67.47% | 0.47 -6.67% | 1.67 254.89% | 2.57 54.21% | 3.14 22.44% | 3.76 19.46% | 4.25 13.24% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.05 | 0.07 62.56% | 0.08 31.14% | 0.08 716.00% | 0.15 192.63% | 0.19 196.47% | 0.21 165.10% | 0.23 178.13% |
| Revenue Q2Q % growth | 154.7M 6.30% | 166.82M 2.12% | 170.13M 6.73% | 172.1M 5.86% | 162.68M 5.16% | 172.52M 3.42% | 179.05M 5.24% | 187.19M 8.77% |
| EBITDA Q2Q % growth | 10.771M -50.04% | 16.33M -46.36% | 17.065M -44.21% | 11.924M -95.44% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 20.847M -1.79% | 29.417M -1.24% | 30.149M 1.89% | 28.639M -89.00% | N/A | N/A | N/A | N/A |
All data in USD
16 analysts have analysed BCRX and the average price target is 21.73 USD. This implies a price increase of 136.41% is expected in the next year compared to the current price of 9.19.
BIOCRYST PHARMACEUTICALS INC (BCRX) will report earnings on 2026-05-06, before the market open.
The consensus EPS estimate for the next earnings of BIOCRYST PHARMACEUTICALS INC (BCRX) is 0.05 USD and the consensus revenue estimate is 154.70M USD.
The expected long term growth rate for BIOCRYST PHARMACEUTICALS INC (BCRX) is 12.29%.